Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Bio-Path Holdings, Inc. BPTH
$1.47
-$0.05 (-3.24%)
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
12019842.00000000
-
week52high
4.48
-
week52low
1.18
-
Revenue
0
-
P/E TTM
-1
-
Beta
1.30276800
-
EPS
-2.21000000
-
Last Dividend
0.00000000
-
Next Earnings Date
15 мая 2023 г. в 12:30
Описание компании
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| HC Wainwright & Co. | Buy | Buy | 19 мая 2022 г. |
| Roth Capital | Buy | 11 мар 2021 г. | |
| HC Wainwright & Co. | Buy | Buy | 25 ноя 2020 г. |
| H.C. Wainwright | Buy | 25 ноя 2020 г. | |
| HC Wainwright & Co. | Buy | Buy | 16 ноя 2020 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Sherwood Aline | A | 10000 | 10000 | 31 мар 2022 г. |
| MORRIS DOUGLAS P | A | 11000 | 11000 | 28 мар 2022 г. |
| Cleaver Heath | A | 10000 | 10000 | 28 мар 2022 г. |
| Aubert Paul | A | 10000 | 10000 | 28 мар 2022 г. |
| Nielsen Peter Henry | A | 90000 | 90000 | 23 мар 2022 г. |
| MORRIS DOUGLAS P | A | 13000 | 13000 | 31 мар 2021 г. |
| Nielsen Peter Henry | A | 100000 | 100000 | 31 мар 2021 г. |
| Cleaver Heath | A | 10000 | 10000 | 31 мар 2021 г. |
| Aubert Paul | A | 10000 | 10000 | 31 мар 2021 г. |
| Molsbergen Tamaro Martina | A | 10000 | 10000 | 31 мар 2021 г. |
Новостная лента
Bio-Path Holdings, Inc. (BPTH) Q1 2023 Earnings Call Transcript
Seeking Alpha
12 мая 2023 г. в 10:06
Bio-Path Holdings, Inc. (NASDAQ:BPTH ) Q1 2023 Earnings Conference Call May 12, 2023 8:30 AM ET Company Participants Will O'Connor - Investor Relations, Stern IR Peter Nielsen - President and Chief Executive Officer Anthony Price - Senior Vice President of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - ROTH MKM Operator Good morning, ladies and gentlemen. Welcome to the Bio-Path Holdings First Quarter 2023 Earnings Conference Call.
Bio-Path Holdings to Announce First Quarter 2023 Financial Results on May 12, 2023
GlobeNewsWire
05 мая 2023 г. в 07:00
HOUSTON, May 05, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, May 12, 2023 at 8:30 a.m. ET to report financial results for the first quarter ended March 31, 2023 and to provide a business overview.
Bio-Path Holdings to Announce Fourth Quarter and Full Year 2022 Financial Results on March 31, 2023
GlobeNewsWire
24 мар 2023 г. в 16:01
HOUSTON, March 24, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc. (NASDAQ: BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Friday, March 31, 2023 at 8:30 a.m. ET to report financial results for the fourth quarter and full year ended December 31, 2022 and to provide a business overview.
Bio-Path Holdings Inc. (BPTH) Q3 2022 Earnings Call Transcript
Seeking Alpha
15 ноя 2022 г. в 11:20
Bio-Path Holdings Inc. (NASDAQ:BPTH ) Q3 2022 Earnings Conference Call November 15, 2022 8:30 AM ET Company Participants Will O'Connor - Stern Investor Relations Peter Nielsen - CEO and CFO Anthony Price - SVP of Finance, Accounting and Administration Conference Call Participants Jonathan Aschoff - Roth Capital Partners Yi Chen - H.C. Wainwright Laura Engel - Stonegate Capital Partners Operator Good morning ladies and gentlemen.
Bio-Path Holdings to Announce Third Quarter 2022 Financial Results on November 15, 2022
GlobeNewsWire
08 ноя 2022 г. в 07:00
HOUSTON, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that it will host a live conference call and audio webcast on Tuesday, November 15, 2022 at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2022 and to provide a business overview.